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Abstract  A 62-year-old female patient received adjuvant chemotherapy after a mastectomy due to a locally 
advanced invasive ductal carcinoma eight years ago. During the follow-up, she complained of extensive backache, 
so a plain radiography was taken. The radiography showed diffuse lytic lesions located primarily around the 
vertebrae and sternum. Given that the bone lesions could be related to osseous metastases of the breast cancer, a 
bone scintigraphy was performed and no positive involvement was observed. Magnetic resonance imaging was 
subsequently applied and diffuse hypointense areas were found on the vertebrae. The patient had also accompanying 
bicytopenia (thrombocytopenia and luecocytopenia), albumin/globulin inversion and hyperglobulinemia. As the 
patient did not have such involvement in regard to her overall body scintigraphy and there were accompanying 
abnormal biochemical parameters, it was concluded that the patient’s bone lesions were an outcome of a 
hematological malignity. Bone marrow aspiration and the biopsy result were found to be consistent with multiple 
myeloma (MM). It was thus confirmed that the lytic lesions were not related to breast cancer but rather MM bone 
lesions. We are able to conclude, based on the case presented herein, that newly-developing bone lesions on patients 
with breast cancer must be approached with suspicion, and their other laboratory analyses and imaging diagnostic 
processes must be evaluated carefully. It is necessary to keep in mind that such a condition might be related to other 
diseases, however rare the occurrence. 
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1. Introduction 
Despite the fact that breast cancer is one of the most 
common cancers worldwide, in recent years related 
mortality has decreased due to advanced imaging systems 
and treatments [1,2]. Seventy percent of patients with 
metastatic breast cancer develop osseous metastasis. Bone 
is the first location of metastasis for around one-fourth of 
the patients. After a follow-up of four years, the 
recurrence rate is found to be 36%, and for most of these, 
the first focus of the recurrence is the skeletal system [3]. 
Multiple myeloma (MM) is a plasma cell malignancy 
characterized by osteolytic bone lesions, cytopenias 
(especially anemia), hypercalcemia and renal insuffiency. 
It involves an increase in abnormal monoclonal plasma 
cells which primarily infiltrate the bone marrow and, 
rarely, other visceral organs, as well as abnormal 
immunoglobulin (Ig) secretion by these pathologic cells. 
Lytic bone lesions are often observed radiologically, 
especially around the proximals of vertebrae and 
extremities [4]. Vertebral column involvement is common 
in MM; hence, if the patient presents with lower back pain 
and backache, MM should be considered during 
differential diagnosis. Twenty-seven percent of all bone 
tumors which biopsied due to bone lesions and 1% of all 
malignities are caused by MM [5]. 
2. Case Report 
A 62-year-old female patient was admitted to the local 
government hospital for a breast lump in July 2007. Due 
to the palpable mass at her lower outer quadrant left-breast, 
an ultrasonography was taken, and she was found to have 
a ‘‘lobular, irregular shaped solid mass, 2.4 cm in size, 
located at the lower outer quadrant left-breast”. An 
excisional biopsy was performed. Pathological diagnosis 
was consistent with invasive ductal carcinoma which was 
low grade, ER, PR and HER2 negative, with no vascular 
or neural invasion. The patient underwent a left modified 
radical mastectomy (MRM) plus axillary lymph node 
dissection in August 2007 at the university hospital. 
Pathological examination showed no sign of a residual 
tumor, however accompanying fibrocystic changes were 
observed. At the same time, thirteen reactive lymph nodes 
were observed. Beginning in September 2007, the patient 
was given 4 cycles of Adriamycin plus cyclophosphamide 
treatment as adjuvant chemotheraphy. Adjuvant radiotheraphy 
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was not recommended. Subsequently, the patient’s follow-
up without treatment was started. The patient had no 
medical complaint for eight years.  
Then, in late 2014, she started to complain of 
widespread lower back pain. The plain radiographic 
examination showed diffuse lytic lesions on the sternum 
and vertebrae. Bone scintigraphy was then performed and 
no pathological involvements were found which could be 
considered metasteses. Diffuse hypointensities with 
heterogeneous enhancement in the peduncle, corpus and 
thoracolumbar vertebrae, observed by means of vertebral 
magnetic resonance imaging (MRI), were initially 
considered to be diffused metastases; however, extramedullary 
hematopoiesis was not conclusively excluded. Following 
the MRI, fluorodeoxyglucose positron emission tomography 
combined with computed tomography (PET-CT) scan was 
performed and pathological involvement, more distinct 
around the vertebral coloumn and sternum and increased 
on the axial skeleton, was observed. The patient’s 
laboratory findings were as follows: leucocyte 6900, 
platelet 78000, MCV 84,3 fL, hemoglobulin (Hb) 9.1 
gr/dL, albumin 3.3 g/dL, globulin 8.1 g/dL, lactate 
dehydrogenase 168 U/L, alkaline phosphatase (ALP) 24 
U/L, creatinine 0.61 mg/dL, calcium 7.5 mg/dL, beta-2 
microglobulin 5.63 mg/L, IgG 61,9 gr/L, IgA 0.5 gr/L, 
IgM 0.173 gr/L, CRP 3.48 mg/L, CA-125 1.1 U/mL, 
CA15-3 15.2 U/Ml and CEA 0.97 ng/mL. Taking into 
account the bicytopenia, normal ALP values and 
albumin/globulin inversion, it was decided that a bone 
marrow aspiration and biopsy should be performed. The 
results of the bone marrow biopsy and aspiration, 
performed in March 2015, were found to be compatible 
with monoclonal plasma cells nodular infiltration. 
Considering the above-mentioned findings, the patient 
was diagnosed with MM. Following the diagnosis, 
zoledronic acid treatment for the lytic lesions on the bones 
and bortezomib plus steroid treatment for the MM was 
begun.  
3. Discussion 
The primary question in this case is which breast cancer 
patients with suspicious osseous metastases should 
undergo bone marrow and/or bone biopsies. Clayer and 
Duncan, in their prospective study, have tried to discover 
the nature of the condition by means of conducting 
biopsies on the newly-developing bone lesions of patients 
with identified localized visceral carcinoma who were 
developing the lesions during their follow-up [6]. Newly-
developing bone lesions were found to be second primary 
cancers on 15% of the patients and 4% of these were 
found to have MM. In consideration of the aforementioned 
results, they suggested that a biopsy of the new-
developing bone lesions must be performed, especially 
when the patient’s primary cancer is breast cancer [6]. 
Guidelines concerning which patients and which 
metastases caused by which tumors require confirmation 
by biopsy are not yet very clear. Many factors can assist 
us in this issue. Radiological properties of metastatic lesions, 
location of the involvement, age of the patient, and 
accompanying laboratory abnormalities (biochemical and 
hematological cytopenia) can be considered such factors. 
In bone scintigraphy, an increase in radiopharmaceutical 
involvement in any part of the skeletal system indicates an 
increase in osteoblastic activity and/or local blood flow. 
Changes in the above-mentioned factors result in 
abnormal bone scintigraphy. While there may be 
osteoblastic and osteolytic lesions in cases of metastatic 
breast cancer, what is observed in cases of multiple 
myeloma are pure osteolytic lesions due to the increase in 
osteoclastic activity during which osteoblastic activity is 
suppressed [7]. Apart from this, a radiotracer is held only 
by active osteoblasts which can cause false imaging in 
cases of multiple myeloma [8]. Despite the presence of 
lytic lesions in our patient around the vertebra and 
sternum, as shown by the plain radiography, there was no 
involvement in the patient’s bone scintigraphy. This is a 
rare occurrence for breast cancer bone metastasis, hence it 
is necessary to diagnose the lytic lesions on bones 
definitively. In connection with increased osteoblastic 
activity in breast cancer patients, two-thirds of the patients 
have increased levels of serum ALP [9,10]. Through the 
same mechanism, as the osteoblastic activity is suppressed 
in cases of MM, no increase in osteoblastic activity is 
observed. Instances of new bone formation in MM are 
quite low, hence the increase in ALP levels are found to 
vary from 4% to 17%. The ALP level in our patient was 
within the normal range. This finding also supported a 
diagnosis of MM [11]. Additionally, in patients with 
metastatic breast cancer, only 16% do not have extra-
skeletal system visceral organ involvement despite their 
diffuse skeletal system involvement, while the majority of 
patients with multiple sclerosis have been found to have 
bone involvements [12]. 
In identifying osteolytic lesions which develop in cases 
of MM, the sensitivity of MRI is remarkably high [13]. 
On the bone scintigraphy taken due to our patient’s 
extensive bone pain, there were no findings indicating the 
spread of the disease to the skeletal system. However, the 
vertebral MRI presented diffuse patchy hypointensities 
with heterogeneous enhancing around the corpus and 
pedincules. There were no scintigraphic involvements 
with bone lesions, while the MRI indicated presence of 
lesions, bringing to mind MM. 
Neoplastic plasma cells which replace bone marrow 
cells suppress the production of normal bone marrow cells, 
possibly causing normochromic normocytic anemia, 
thrombocytopenia and leucopenia in the meantime. 
Accordingly, examinations of the patients have revealed 
anemia (Hb 9.1 gr/dl) and thrombocytopenia (78000). 
Furthermore, albumin (3.1gr/dl) was found to be low, 
globulin (8.1 gr/dl) was high, and the sedimentation rate 
was also high. MM often shows abnormal monoclonal 
immunoglobulin (Ig) synthesis; IgG was found to be high 
in 60% of the patients, IgA in 20% of the patients, and  
20% of the patients had high Ig light chains [14]. What 
pointed to MM in our patient were anemia, 
albumin/globulin inversion, thrombocytopenia, high 
sedimentation rate and weight loss. One of the 
immunoglobulin levels related to MM which was 
analyzed, IgG, was found to be high (61.9 g/l). Results of 
the bone marrow aspiration and biopsy were consistent 
with plasma cell myeloma.  
In conclusion, biopsies from metastatic lesions must be 
considered wherever possible for the treatment of 
metastatic disease which develops during follow-up of 
patients treated for localized carcinoma. If a biopsy is 
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contraindicated, secondary primary diseases must be 
carefully looked into and any additional examinations 
must be included as well. 
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